Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
The US Food and Drug Administration (FDA) has approved a new weight-loss drug from the pharmaceutical company Vivus.
The FDA approved Qsymia for patients who are overweight or obese and have at least one other weight-related condition.
The approval comes after the FDA gave another anti-obesity drug, Belviq, the green light last month.
The approvals are the first in the US for 13 years.
The FDA said that two studies conducted on patients who took Qsymia, along with changing their diet and increasing exercise, showed an average weight loss of 6.7% and 8.9%.
However, the drug can increase heart rate and will therefore not be recommended for patients with heart disease or who have recently suffered a stroke.
http://www.bbc.co.uk/news/world-us-canada-18881232
The FDA approved Qsymia for patients who are overweight or obese and have at least one other weight-related condition.
The approval comes after the FDA gave another anti-obesity drug, Belviq, the green light last month.
The approvals are the first in the US for 13 years.
The FDA said that two studies conducted on patients who took Qsymia, along with changing their diet and increasing exercise, showed an average weight loss of 6.7% and 8.9%.
However, the drug can increase heart rate and will therefore not be recommended for patients with heart disease or who have recently suffered a stroke.
http://www.bbc.co.uk/news/world-us-canada-18881232